Global Multiple Myeloma Therapeutics Market Growth (Status and Outlook) 2024-2030

2024

Global Multiple Myeloma Therapeutics Market Growth (Status and Outlook) 2024-2030

Name: Global Multiple Myeloma Therapeutics Market Growth (Status and Outlook) 2024-2030
Brand: Bonafide Research
SKU: 95001563
Price: 3450 USD
Availability: InStock
Rating: 5 (22.25 reviews)

The global Multiple Myeloma Therapeutics market, valued at US$ 26,680 million in 2023, is expanding with ongoing research and development of treatments for this type of blood cance

Bonafide Trust
10-09-2024
Pages : 116
Figures : 79
Tables : 102
Region : Global
Category : Lifescience & Healthcare
Healthcare

Schedule a Call

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global multiple myeloma therapeutics market is witnessing substantial growth, propelled by rising incidences of multiple myeloma, advancements in diagnostic technologies, and the introduction of innovative treatment options. Multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow, continues to garner significant attention due to an increasing number of diagnosed cases2. Enhanced awareness and improved diagnostic criteria contribute to earlier detection, resulting in a rising demand for effective therapeutics1. The market is segmented based on drug classes, including immunomodulators, proteasome inhibitors, anti-CD38 monoclonal antibodies, alkylating agents, and others. These drugs target cancer cells at various stages and mechanisms, offering a comprehensive approach to treatment. Immunomodulators, such as lenalidomide, play a crucial role in enhancing the immune response against cancer cells1. Proteasome inhibitors, including drugs like bortezomib, are designed to disrupt the protein degradation pathway in cancer cells, leading to cell death. Anti-CD38 monoclonal antibodies have shown significant efficacy in targeting specific proteins on the surface of myeloma cells, marking a significant advancement in targeted cancer therapy. The market is also bolstered by a robust pipeline of new and effective therapies that promise improved treatment outcomes2. The increasing investment in R&D by pharmaceutical companies, regulatory approvals, and the launch of novel therapies further drive market growth2. North America holds a dominant position due to its advanced healthcare infrastructure, high healthcare expenditure, and strong presence of major pharmaceutical players. Europe follows closely, driven by extensive research activities and favorable government policies promoting cancer treatment1. Asia-Pacific is emerging rapidly as a promising market, fueled by growing healthcare awareness, rising disposable incomes, and increasing diagnostic capabilities4. The integration of advanced technologies such as AI and machine learning in diagnostic tools and personalized medicine significantly enhances the management and treatment of multiple myeloma.

According to Publisher, the global Multiple Myeloma Therapeutics market size was valued at US$ 26680 million in 2023. With growing demand in downstream market, the Multiple Myeloma Therapeutics is forecast to a readjusted size of US$ 55510 million by 2030 with a CAGR of 11.0% during review period. The research report highlights the growth potential of the global Multiple Myeloma Therapeutics market. Multiple Myeloma Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Multiple Myeloma Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Multiple Myeloma Therapeutics market.Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

The global multiple myeloma therapeutics market, segmented by drug type, displays distinctive growth patterns driven by various therapeutic classes. Immunomodulators are pivotal in treating multiple myeloma by enhancing the immune response against cancer cells. Drugs like lenalidomide (Revlimid) have become a cornerstone in treatment regimens, often combined with other therapies to improve outcomes2. Proteasome inhibitors, such as bortezomib (Velcade) and carfilzomib (Kyprolis), target the protein degradation pathway in cancer cells, leading to cell death. These inhibitors are particularly effective in treating relapsed and refractory multiple myeloma. Anti-CD38 monoclonal antibodies, including daratumumab (Darzalex), have revolutionized the treatment landscape by specifically targeting the CD38 protein on myeloma cells. Alkylating agents like melphalan and cyclophosphamide interfere with DNA replication, making them crucial in stem cell transplant preparations and as part of combination regimens. Other therapeutic classes include histone deacetylase (HDAC) inhibitors like panobinostat, which modify gene expression to inhibit cancer cell growth. The market is also bolstered by emerging therapies such as CAR-T cell therapies, which have shown promising results in clinical trials by reprogramming a patient's immune cells to target cancer. The increasing understanding of multiple myeloma pathophysiology, coupled with ongoing research and development, drives innovation and the introduction of new treatment modalities. The continuous expansion of therapeutic options, including personalized medicine approaches and combination therapies, underscores the market's growth trajectory. Geographically, North America dominates the market due to advanced healthcare infrastructure, high healthcare expenditure, and significant investment in oncology research. Europe follows closely, driven by robust research activities and supportive government policies promoting cancer treatment. Asia-Pacific is emerging as a key region, propelling market growth through increasing healthcare awareness, rising disposable incomes, and expanding diagnostic capabilities.

The global multiple myeloma therapeutics market, segmented by application, reveals varied growth trajectories shaped by the need for specialized treatments across different stages of the disease. The three primary applications are newly diagnosed patients, relapsed/refractory multiple myeloma, and maintenance therapy. For newly diagnosed patients, treatment options usually begin with induction therapy, which aims to reduce disease burden and prepare patients for potential stem cell transplantation. This segment benefits significantly from advancements in combination therapies, including immunomodulators like lenalidomide and proteasome inhibitors like bortezomib, designed to enhance treatment efficacy in initial stages. Among relapsed/refractory multiple myeloma patients, the therapeutic landscape is marked by the necessity for advanced and tailored treatments to manage cases where conventional therapies fail. Novel treatments such as anti-CD38 monoclonal antibodies (e.g., daratumumab), CAR-T cell therapies, and HDAC inhibitors (e.g., panobinostat) are pivotal in this segment, offering targeted approaches that address specific pathways and provide substantial clinical benefits. This area particularly emphasizes ongoing research and the introduction of new therapies that improve patient outcomes and manage relapse effectively. Maintenance therapy focuses on preventing disease recurrence after initial successful treatment by maintaining minimal residual disease levels. Therapeutics such as thalidomide, lenalidomide, and proteasome inhibitors play crucial roles in this segment, extending progression-free survival and enhancing overall patient quality of life. Technological advancements in personalized medicine, including genetic profiling and biomarker identification, enable the development of more precise and effective maintenance regimens. Geographically, the market's growth is reflected across regions: North America remains dominant due to its sophisticated healthcare infrastructure and significant investment in cancer research. Europe follows closely, driven by strong research activities and supportive government policies. Asia-Pacific, emerging as a promising market, experiences growth fueled by increasing healthcare awareness, rising disposable incomes, and improved diagnostic capabilities. The continuous expansion in therapeutic options and the focus on innovative, patient-centric treatments underline the market's substantial growth potential.

The global multiple myeloma therapeutics market exhibits diverse growth trajectories across various regions, driven by differences in healthcare infrastructure, patient demographics, and governmental policies. North America stands as the dominant region, primarily due to its advanced healthcare systems, high healthcare expenditure, and the strong presence of major pharmaceutical companies investing heavily in oncology research. The region benefits from robust clinical trials, innovative drug development, and widespread adoption of advanced therapeutic options2. Europe follows closely, with countries such as Germany, France, and the UK leading the charge owing to the region's extensive research activities and supportive healthcare policies. The market in Europe is bolstered by a high awareness of the disease, early diagnosis capabilities, and a strong focus on developing and implementing innovative treatments3. Asia-Pacific is experiencing rapid growth, fueled by increasing healthcare awareness, rising disposable incomes, and expanding diagnostic capabilities in countries like China, Japan, and India. Government initiatives aimed at enhancing cancer treatment accessibility and significant investments in healthcare infrastructure contribute to the market's expansion in this region3. In Latin America and the Middle East & Africa, the market shows notable potential as these regions work to improve their healthcare systems and increase access to advanced cancer therapies. Countries like Brazil and Mexico in Latin America, and Saudi Arabia and the UAE in the Middle East, are focusing on integrating cutting-edge treatments and expanding diagnostic facilities2. The global emphasis on personalized medicine, alongside advancements in diagnostic tools and therapeutic options, further drives market growth across these regions3. The increasing prevalence of multiple myeloma worldwide, coupled with the development of novel therapies such as CAR-T cell therapies and monoclonal antibodies, highlights the importance of continued research and investment in this field.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Research Analyst

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Multiple Myeloma Therapeutics Market Size 2019-2030
2.1.2 Multiple Myeloma Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Multiple Myeloma Therapeutics Segment by Type
2.2.1 Chemotherapy
2.2.2 Radiation
2.2.3 Stem Cell Transplant
2.2.4 Other Supportive Treatments
2.3 Multiple Myeloma Therapeutics Market Size by Type
2.3.1 Multiple Myeloma Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Multiple Myeloma Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Multiple Myeloma Therapeutics Market Size by Application
2.5.1 Multiple Myeloma Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
3 Multiple Myeloma Therapeutics Market Size by Player
3.1 Multiple Myeloma Therapeutics Market Size Market Share by Players
3.1.1 Global Multiple Myeloma Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Multiple Myeloma Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Multiple Myeloma Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Multiple Myeloma Therapeutics by Regions
4.1 Multiple Myeloma Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Multiple Myeloma Therapeutics Market Size Growth (2019-2024)
4.3 APAC Multiple Myeloma Therapeutics Market Size Growth (2019-2024)
4.4 Europe Multiple Myeloma Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Multiple Myeloma Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Multiple Myeloma Therapeutics Market Size by Country (2019-2024)
5.2 Americas Multiple Myeloma Therapeutics Market Size by Type (2019-2024)
5.3 Americas Multiple Myeloma Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Multiple Myeloma Therapeutics Market Size by Region (2019-2024)
6.2 APAC Multiple Myeloma Therapeutics Market Size by Type (2019-2024)
6.3 APAC Multiple Myeloma Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Multiple Myeloma Therapeutics by Country (2019-2024)
7.2 Europe Multiple Myeloma Therapeutics Market Size by Type (2019-2024)
7.3 Europe Multiple Myeloma Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Multiple Myeloma Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Multiple Myeloma Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Multiple Myeloma Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Multiple Myeloma Therapeutics Market Forecast
10.1 Global Multiple Myeloma Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Multiple Myeloma Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Multiple Myeloma Therapeutics Forecast
10.1.3 APAC Multiple Myeloma Therapeutics Forecast
10.1.4 Europe Multiple Myeloma Therapeutics Forecast
10.1.5 Middle East & Africa Multiple Myeloma Therapeutics Forecast
10.2 Americas Multiple Myeloma Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Multiple Myeloma Therapeutics Market Forecast
10.2.2 Canada Multiple Myeloma Therapeutics Market Forecast
10.2.3 Mexico Multiple Myeloma Therapeutics Market Forecast
10.2.4 Brazil Multiple Myeloma Therapeutics Market Forecast
10.3 APAC Multiple Myeloma Therapeutics Forecast by Region (2025-2030)
10.3.1 China Multiple Myeloma Therapeutics Market Forecast
10.3.2 Japan Multiple Myeloma Therapeutics Market Forecast
10.3.3 Korea Multiple Myeloma Therapeutics Market Forecast
10.3.4 Southeast Asia Multiple Myeloma Therapeutics Market Forecast
10.3.5 India Multiple Myeloma Therapeutics Market Forecast
10.3.6 Australia Multiple Myeloma Therapeutics Market Forecast
10.4 Europe Multiple Myeloma Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Multiple Myeloma Therapeutics Market Forecast
10.4.2 France Multiple Myeloma Therapeutics Market Forecast
10.4.3 UK Multiple Myeloma Therapeutics Market Forecast
10.4.4 Italy Multiple Myeloma Therapeutics Market Forecast
10.4.5 Russia Multiple Myeloma Therapeutics Market Forecast
10.5 Middle East & Africa Multiple Myeloma Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Multiple Myeloma Therapeutics Market Forecast
10.5.2 South Africa Multiple Myeloma Therapeutics Market Forecast
10.5.3 Israel Multiple Myeloma Therapeutics Market Forecast
10.5.4 Turkey Multiple Myeloma Therapeutics Market Forecast
10.5.5 GCC Countries Multiple Myeloma Therapeutics Market Forecast
10.6 Global Multiple Myeloma Therapeutics Forecast by Type (2025-2030)
10.7 Global Multiple Myeloma Therapeutics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Janssen Biotech, Inc.
11.1.1 Janssen Biotech, Inc. Company Information
11.1.2 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Product Offered
11.1.3 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Janssen Biotech, Inc. Main Business Overview
11.1.5 Janssen Biotech, Inc. Latest Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Information
11.2.2 Bristol-Myers Squibb Multiple Myeloma Therapeutics Product Offered
11.2.3 Bristol-Myers Squibb Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bristol-Myers Squibb Main Business Overview
11.2.5 Bristol-Myers Squibb Latest Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Multiple Myeloma Therapeutics Product Offered
11.3.3 Novartis AG Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Novartis AG Main Business Overview
11.3.5 Novartis AG Latest Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Information
11.4.2 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Product Offered
11.4.3 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bristol-Myers Squibb Company Main Business Overview
11.4.5 Bristol-Myers Squibb Company Latest Developments
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Information
11.5.2 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Product Offered
11.5.3 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Millennium Pharmaceuticals Main Business Overview
11.5.5 Millennium Pharmaceuticals Latest Developments
11.6 Celgene Corporation
11.6.1 Celgene Corporation Company Information
11.6.2 Celgene Corporation Multiple Myeloma Therapeutics Product Offered
11.6.3 Celgene Corporation Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Celgene Corporation Main Business Overview
11.6.5 Celgene Corporation Latest Developments
11.7 Kesios Therapeutics Limited
11.7.1 Kesios Therapeutics Limited Company Information
11.7.2 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Product Offered
11.7.3 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Kesios Therapeutics Limited Main Business Overview
11.7.5 Kesios Therapeutics Limited Latest Developments
11.8 Amgene, Inc.
11.8.1 Amgene, Inc. Company Information
11.8.2 Amgene, Inc. Multiple Myeloma Therapeutics Product Offered
11.8.3 Amgene, Inc. Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Amgene, Inc. Main Business Overview
11.8.5 Amgene, Inc. Latest Developments
11.9 Genzyme Corporation
11.9.1 Genzyme Corporation Company Information
11.9.2 Genzyme Corporation Multiple Myeloma Therapeutics Product Offered
11.9.3 Genzyme Corporation Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Genzyme Corporation Main Business Overview
11.9.5 Genzyme Corporation Latest Developments
11.10 Juno Therapeutics
11.10.1 Juno Therapeutics Company Information
11.10.2 Juno Therapeutics Multiple Myeloma Therapeutics Product Offered
11.10.3 Juno Therapeutics Multiple Myeloma Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Juno Therapeutics Main Business Overview
11.10.5 Juno Therapeutics Latest Developments
12 Research Findings and Conclusion

Table 1. Multiple Myeloma Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Chemotherapy
Table 3. Major Players of Radiation
Table 4. Major Players of Stem Cell Transplant
Table 5. Major Players of Other Supportive Treatments
Table 6. Multiple Myeloma Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 7. Global Multiple Myeloma Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 8. Global Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Table 9. Multiple Myeloma Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 10. Global Multiple Myeloma Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 11. Global Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Table 12. Global Multiple Myeloma Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 13. Global Multiple Myeloma Therapeutics Revenue Market Share by Player (2019-2024)
Table 14. Multiple Myeloma Therapeutics Key Players Head office and Products Offered
Table 15. Multiple Myeloma Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Multiple Myeloma Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 19. Global Multiple Myeloma Therapeutics Market Size Market Share by Regions (2019-2024)
Table 20. Global Multiple Myeloma Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 21. Global Multiple Myeloma Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 22. Americas Multiple Myeloma Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 23. Americas Multiple Myeloma Therapeutics Market Size Market Share by Country (2019-2024)
Table 24. Americas Multiple Myeloma Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 25. Americas Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Table 26. Americas Multiple Myeloma Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 27. Americas Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Table 28. APAC Multiple Myeloma Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 29. APAC Multiple Myeloma Therapeutics Market Size Market Share by Region (2019-2024)
Table 30. APAC Multiple Myeloma Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 31. APAC Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Table 32. APAC Multiple Myeloma Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 33. APAC Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Table 34. Europe Multiple Myeloma Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 35. Europe Multiple Myeloma Therapeutics Market Size Market Share by Country (2019-2024)
Table 36. Europe Multiple Myeloma Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 37. Europe Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Table 38. Europe Multiple Myeloma Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 39. Europe Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Table 40. Middle East & Africa Multiple Myeloma Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 41. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Region (2019-2024)
Table 42. Middle East & Africa Multiple Myeloma Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 43. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Table 44. Middle East & Africa Multiple Myeloma Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 45. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Table 46. Key Market Drivers & Growth Opportunities of Multiple Myeloma Therapeutics
Table 47. Key Market Challenges & Risks of Multiple Myeloma Therapeutics
Table 48. Key Industry Trends of Multiple Myeloma Therapeutics
Table 49. Global Multiple Myeloma Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 50. Global Multiple Myeloma Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 51. Global Multiple Myeloma Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 52. Global Multiple Myeloma Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 53. Janssen Biotech, Inc. Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 54. Janssen Biotech, Inc. Multiple Myeloma Therapeutics Product Offered
Table 55. Janssen Biotech, Inc. Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 56. Janssen Biotech, Inc. Main Business
Table 57. Janssen Biotech, Inc. Latest Developments
Table 58. Bristol-Myers Squibb Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 59. Bristol-Myers Squibb Multiple Myeloma Therapeutics Product Offered
Table 60. Bristol-Myers Squibb Main Business
Table 61. Bristol-Myers Squibb Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 62. Bristol-Myers Squibb Latest Developments
Table 63. Novartis AG Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 64. Novartis AG Multiple Myeloma Therapeutics Product Offered
Table 65. Novartis AG Main Business
Table 66. Novartis AG Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 67. Novartis AG Latest Developments
Table 68. Bristol-Myers Squibb Company Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 69. Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Product Offered
Table 70. Bristol-Myers Squibb Company Main Business
Table 71. Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 72. Bristol-Myers Squibb Company Latest Developments
Table 73. Millennium Pharmaceuticals Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 74. Millennium Pharmaceuticals Multiple Myeloma Therapeutics Product Offered
Table 75. Millennium Pharmaceuticals Main Business
Table 76. Millennium Pharmaceuticals Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 77. Millennium Pharmaceuticals Latest Developments
Table 78. Celgene Corporation Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 79. Celgene Corporation Multiple Myeloma Therapeutics Product Offered
Table 80. Celgene Corporation Main Business
Table 81. Celgene Corporation Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 82. Celgene Corporation Latest Developments
Table 83. Kesios Therapeutics Limited Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 84. Kesios Therapeutics Limited Multiple Myeloma Therapeutics Product Offered
Table 85. Kesios Therapeutics Limited Main Business
Table 86. Kesios Therapeutics Limited Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 87. Kesios Therapeutics Limited Latest Developments
Table 88. Amgene, Inc. Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 89. Amgene, Inc. Multiple Myeloma Therapeutics Product Offered
Table 90. Amgene, Inc. Main Business
Table 91. Amgene, Inc. Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 92. Amgene, Inc. Latest Developments
Table 93. Genzyme Corporation Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 94. Genzyme Corporation Multiple Myeloma Therapeutics Product Offered
Table 95. Genzyme Corporation Main Business
Table 96. Genzyme Corporation Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 97. Genzyme Corporation Latest Developments
Table 98. Juno Therapeutics Details, Company Type, Multiple Myeloma Therapeutics Area Served and Its Competitors
Table 99. Juno Therapeutics Multiple Myeloma Therapeutics Product Offered
Table 100. Juno Therapeutics Main Business
Table 101. Juno Therapeutics Multiple Myeloma Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 102. Juno Therapeutics Latest Developments
List of

Figure 1. Multiple Myeloma Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Multiple Myeloma Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Multiple Myeloma Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Multiple Myeloma Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Multiple Myeloma Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Multiple Myeloma Therapeutics Market Size Market Share by Type in 2023
Figure 10. Multiple Myeloma Therapeutics in Hospitals
Figure 11. Global Multiple Myeloma Therapeutics Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Multiple Myeloma Therapeutics in Clinics
Figure 13. Global Multiple Myeloma Therapeutics Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Multiple Myeloma Therapeutics in Others
Figure 15. Global Multiple Myeloma Therapeutics Market: Others (2019-2024) & ($ Millions)
Figure 16. Global Multiple Myeloma Therapeutics Market Size Market Share by Application in 2023
Figure 17. Global Multiple Myeloma Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Multiple Myeloma Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Multiple Myeloma Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Multiple Myeloma Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Multiple Myeloma Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Multiple Myeloma Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Multiple Myeloma Therapeutics Value Market Share by Country in 2023
Figure 24. United States Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Multiple Myeloma Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Multiple Myeloma Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Multiple Myeloma Therapeutics Market Size Market Share by Application in 2023
Figure 31. China Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Multiple Myeloma Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Figure 40. Germany Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Multiple Myeloma Therapeutics Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Multiple Myeloma Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Multiple Myeloma Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Multiple Myeloma Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Multiple Myeloma Therapeutics Market Size Market Share Forecast by Application (2025-2030)

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted